Answers are grounded in this paper and cite their sources.
Inflammatory bowel disease (IBD) involves impaired intestinal barrier function and microbial imbalance, with microbiota-derived bile acids (BAs) serving as key mediators of host-microbe crosstalk. Garcinol (GIE) has anti-inflammatory activity, yet its influence on microbiota-metabolite signaling remains unclear. Using dextran sulfate sodium (DSS)-treated mice, we integrated 16S rRNA sequencing, untargeted and targeted BA metabolomics, and RNA sequencing. Antibiotic treatment and fecal microbiota transplantation (FMT) were used to investigate the potential contribution of the gut microbiota, while deoxycholic acid (DCA) supplementation and FXR-related interventions examined downstream signaling. GIE attenuated colitis, reduced inflammation, and preserved epithelial barrier integrity. It partially corrected gut microbial dysbiosis and altered taxa linked to BA metabolism. GIE altered fecal BA profiles, including DCA levels, while transcriptomic analysis revealed changes in BA-related pathways, including FXR signaling. Under antibiotic treatment, GIE-associated improvements were not statistically evident across several disease-related outcomes, whereas FMT from GIE-treated donors partially reproduced its protective effects. DCA alleviated colitis and increased FXR/SHP protein levels and FXR-related target-gene expression, while pharmacological FXR inhibition attenuated these responses. Collectively, these findings suggest that gut microbiota-associated changes in BA metabolism and host FXR signaling may contribute to the protective effects of GIE against DSS-induced colitis.
No takes yet. Share an insight, caveat, or question.
Lou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: